Arca
Skip to content
Tools
Tools

AVPR1A, AVPR1B: Vasopressin V1 receptor

Family in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on AVPR1A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 1

Approved1

  • Terlipressin

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        TerlipressinApprovedMallinckrodtProtein or peptideBinding agentVasopressin V1 receptor binding agent16

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Terlipressin vs Placebo to Reduce Bleeding in Fibroid SurgeryTerlipressinNot applicableNot yet recruitingSevil CankayaAug 5, 2026
        Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver TransplantationTerlipressinNot applicableRecruitingIstanbul Medipol University HospitalDec 26, 2025
        Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal DysfunctionTerlipressinNot applicableNot yet recruitingGeneral Hospital of Shenyang Military RegionNov 26, 2025
        Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)TerlipressinNot applicableNot yet recruitingInstitute of Liver and Biliary Sciences, IndiaSep 17, 2025
        National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II TrialTerlipressinPhase 2Not yet recruitingInstitute of Liver and Biliary Sciences, IndiaAug 20, 2025
        National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III TrialTerlipressinPhase 3Not yet recruitingInstitute of Liver and Biliary Sciences, IndiaJul 20, 2025
        Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney TransplantationTerlipressinNot applicableActive, not recruitingBeijing Friendship HospitalMar 4, 2025
        Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal BleedTerlipressinPhase 2 / Phase 3Not yet recruitingInstitute of Liver and Biliary Sciences, IndiaFeb 7, 2025

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2111456, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.